CDK6 and neoplasm: CDK4 and CDK6 inhibitors that target cell cycle mechanisms have already been introduced into the clinic and used to treat breast cancer, and may have a profound impact on targeted therapies for other tumor types (Álvarez-Fernández and Malumbres, 2020).